Allianz Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Allianz Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Buy	+9,300	New	+$193K	﹤0.01%	2093
2025 Q4	–	Sell	-15,200	Closed	-$234K	–	2086
2025 Q3	$234K	Buy	+15,200	New	+$199K	﹤0.01%	1941
2025 Q1	–	Sell	-19,500	Closed	-$258K	–	2347
2024 Q4	$258K	Hold	19,500	–	–	﹤0.01%	2043
2024 Q3	$375K	Sell	19,500 -10,800	-36%	-$223K	﹤0.01%	1930
2024 Q2	$622K	Hold	30,300	–	–	﹤0.01%	1761
2024 Q1	$721K	Sell	30,300 -700	-2%	-$15.6K	﹤0.01%	1508
2023 Q4	$670K	Buy	+31,000	New	+$477K	﹤0.01%	1752
2023 Q3	–	Sell	-26,800	Closed	-$561K	–	2257
2023 Q2	$561K	Buy	26,800 +6,800	+34%	+$142K	﹤0.01%	1702
2023 Q1	$422K	Buy	20,000 +4,000	+25%	+$99.5K	﹤0.01%	1933
2022 Q4	$407K	Hold	16,000	–	–	﹤0.01%	1767
2022 Q3	$384K	Sell	16,000 -92,655	-85%	-$2.08M	﹤0.01%	1568
2022 Q2	$2.09M	Buy	108,655 +9,145	+9%	+$152K	﹤0.01%	1411
2022 Q1	$1.73M	Buy	99,510 +25,280	+34%	+$426K	﹤0.01%	1640
2021 Q4	$1.62M	Buy	+74,230	New	+$1.37M	﹤0.01%	1697

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Allianz Asset Management's SNDX Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 9,300 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #2093 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in SNDX as recently as Q3 2025.

Allianz Asset Management first reported a position in SNDX in Q4 2021 and has held it in 14 quarters since. The position peaked at $2.09M in Q2 2022. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Allianz Asset Management held 9,300 shares of Syndax Pharmaceuticals worth $203K as of Q2 2026.
Syndax Pharmaceuticals was a new Allianz Asset Management position in Q2 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2093 holding.
Allianz Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
Allianz Asset Management's Syndax Pharmaceuticals position peaked at $2.09M in Q2 2022.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.